• Read more about HIPEC

Short Title: HIPEC

To collect patient specimens prior to and after HIPEC procedure, along with gastric cancer samples that are from non-HIPEC procedures to test for novel therapeutic additions to the current standard of care procedures. The focus is to find potential targets by studying the characteristics of the disease metastasis which will allow for better treatment options in the future.

Study Number:

HIPEC

Study Status:

Enrolling

Treatment Agent:

Hyperthermic Intraperitoneal Chemotherapy

Resources and Links

National Clinical Trial Identified Number: Not available

Disease:

• Gastric Cancer,
• Peritoneal Metastasis

Study Phase:

Not applicable

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Young Ki Hong, MD, MPH, FACS, FSSO

Department:

• Surgical Oncology

• Read more about SourSop

Short Title: Soursop

The study will determine if there is a reduction in malignant cell burden when patients with relapsed and/or refractory acute myeloid leukemia (AML) or multiple myeloma (MM) consume tea made from the dried leaves of Annona muricata (Soursop). The study goal is to determine the safety and anti-neoplastic efficacy of Annona muricata tea when taken in escalating frequency over a period of 21 days by patients with relapsed/refractory AML or MM for whom there are no standard therapeutic options.

Study Number:

SourSop

Study Status:

Enrolling

Treatment Agent:

Soursop tea

Resources and Links

National Clinical Trial Identified Number: Not available at this time

Disease:

• Acute Myeloid Leukemia ,
• Multiple Myeloma

Study Phase:

Not applicable

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Roger K. Strair, MD, PhD

Department:

• Hematology and Medical Oncology

• Read more about EA7211 STRASS II

Short Title: STRASS II

This is a multicenter, randomized, open label phase lll trial to assess whether preoperative chemotherapy, as an adjunct to curative-intent surgery, improves the prognosis of high risk DDLPS (dedifferentiated Liposarcoma) and LMS (Leiomyosarcoma) patients as measured by disease free survival.

After confirmation of eligibility criteria, patients will be randomized to either the standard arm or experimental arm.

Standard arm:

• Large en-bloc curative-intent surgery within 4 weeks following randomization- Experimental arm

Experimental arm:

• 3 cycles of neoadjuvant chemotherapy starting within 2 weeks following randomization:

  • High grade LPS: ADM (doxorubicin) 75 mg/m2 (or the equivalent EpiADM 120 mg/m2) + ifosfamide 9 g/m3 Q3 weeks.
  • LMS: ADM 75 mg/m2 + DTIC (dacarbazine) 1 g/m2 Q3 weeks
• re-assessment of operability
• curative-intent surgery within 3-6 weeks of last cycle of chemotherapy

Study Number:

EA7211

Study Status:

Enrolling

Treatment Agent:

Surgery, Preoperative chemotherapy

Resources and Links

National Clinical Trial Identified Number: NCT04031677

Disease:

• Retroperitoneal Sarcoma,
• Liposarcoma,
• Leiomyosarcoma

Study Phase:

III

researchcancer@cooperhealth.edu

Hide from Search:

Off

Physician Name:

• Madeline B. Torres, MD